Compass Pathways Archives -

Compass Pathways has reported that its drug for treatment-resistant depression (TRD) based on magic mushroom ingredient psilocybin was

Compass points to positive psilocybin trial, but shares fall

https://pharmaphorum.com/news/compass-points-to-positive-psilocybin-trial-but-shares-fall/

The active compound in magic mushrooms – psilocybin – seems to be at least as effective as a

Magic mushroom compound matches antidepressant in clinical trial

https://pharmaphorum.com/news/magic-mushroom-compound-matches-antidepressant-in-clinical-trial/

Compass Pathways and its potential magic mushroom depression drug went public last week – and now psychedelic therapy

MindMed aims for Nasdaq listing after Compass’ magic mushroom-fuelled IPO

https://pharmaphorum.com/news/mindmed-aims-for-nasdaq-listing-after-compass-magic-mushroom-fuelled-ipo/

UK biotech Compass Pathways is planning a $100 million US IPO as it seeks to further develop its

Compass plans $100m IPO to fund magic mushroom depression drug

https://pharmaphorum.com/news/compass-plans-100m-ipo-to-fund-magic-mushroom-depression-drug/

Compass Pathways